These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 19617248)

  • 1. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method.
    Bednarek E; Sitkowski J; Bocian W; Mulloy B; Kozerski L
    J Pharm Biomed Anal; 2010 Nov; 53(3):302-8. PubMed ID: 20417048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy.
    Beyer T; Diehl B; Randel G; Humpfer E; Schäfer H; Spraul M; Schollmayer C; Holzgrabe U
    J Pharm Biomed Anal; 2008 Sep; 48(1):13-9. PubMed ID: 18678460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin.
    Gray A; Litinas E; Jeske W; Fareed J; Hoppensteadt D
    Clin Appl Thromb Hemost; 2012; 18(2):166-73. PubMed ID: 22311630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
    Shen Y; Kang J
    Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants.
    Zang Q; Keire DA; Wood RD; Buhse LF; Moore CM; Nasr M; Al-Hakim A; Trehy ML; Welsh WJ
    J Pharm Biomed Anal; 2011 Apr; 54(5):1020-9. PubMed ID: 21215547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple fluorescence assay for quantification of OSCS in heparin.
    Lühn S; Schiemann S; Alban S
    Anal Bioanal Chem; 2011 Jan; 399(2):673-80. PubMed ID: 20552175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of crude heparin by (1)H NMR, capillary electrophoresis, and strong-anion-exchange-HPLC for contamination by over sulfated chondroitin sulfate.
    Keire DA; Trehy ML; Reepmeyer JC; Kolinski RE; Ye W; Dunn J; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2010 Mar; 51(4):921-6. PubMed ID: 19959313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of currently marketed heparin products: key tests for LMWH quality assurance.
    Ye H; Toby TK; Sommers CD; Ghasriani H; Trehy ML; Ye W; Kolinski RE; Buhse LF; Al-Hakim A; Keire DA
    J Pharm Biomed Anal; 2013 Nov; 85():99-107. PubMed ID: 23917037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin sodium compliance to the new proposed USP monograph: elucidation of a minor structural modification responsible for a process dependent 2.10 ppm NMR signal.
    Mourier PA; Guichard OY; Herman F; Viskov C
    J Pharm Biomed Anal; 2011 Jan; 54(2):337-44. PubMed ID: 20934294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved impurity fingerprinting of heparin by high resolution (1)H NMR spectroscopy.
    Bigler P; Brenneisen R
    J Pharm Biomed Anal; 2009 May; 49(4):1060-4. PubMed ID: 19211212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis.
    Somsen GW; Tak YH; Toraño JS; Jongen PM; de Jong GJ
    J Chromatogr A; 2009 May; 1216(18):4107-12. PubMed ID: 19272607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of possible economically motivated adulterants in heparin sodium and low molecular weight heparins with a colorimetric microplate based assay.
    Sommers CD; Keire DA
    Anal Chem; 2011 Sep; 83(18):7102-8. PubMed ID: 21819047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin identification test and purity test for OSCS in heparin sodium and heparin calcium by weak anion-exchange high-performance liquid chromatography.
    Hashii N; Kawasaki N; Itoh S; Qin Y; Fujita N; Hattori T; Miyata K; Bando A; Sekimoto Y; Hama T; Kashimura M; Tatsumi M; Mabuchi K; Namekawa H; Sakai T; Hirose M; Dobashi S; Shimahashi H; Koyama S; Herr SO; Kawai K; Yoden H; Yamaguchi T
    Biologicals; 2010 Sep; 38(5):539-43. PubMed ID: 20452241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method.
    Sitkowski J; Bednarek E; Bocian W; Kozerski L
    J Med Chem; 2008 Dec; 51(24):7663-5. PubMed ID: 19055319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and generic anticoagulants and biosimilars: safety considerations.
    Kalodiki E; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):136-9. PubMed ID: 21159711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.